QS Investors’s Health Catalyst HCAT Stock Holding History

QS Investors’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,077	Closed	-$221K	–	1212
2020 Q4	$221K	Buy	+5,077	New	+$187K	﹤0.01%	1085

Other funds holding HCAT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

QS Investors's HCAT Position: Q1 2021 in Review

QS Investors sold out of Health Catalyst (HCAT) in Q1 2021, closing a stake of 5,077 shares — an estimated $221K sold.

QS Investors first reported a position in HCAT in Q4 2020 and held it in 1 quarter. The position peaked at $221K in Q4 2020. 190 funds tracked by Wall St. Rank hold HCAT as of Q1 2021.

QS Investors reported no remaining Health Catalyst position as of Q1 2021 after selling out during the quarter.
QS Investors sold 5,077 Health Catalyst shares in Q1 2021, an estimated $221K.
QS Investors first reported a position in Health Catalyst in Q4 2020 and held it in 1 quarter.
QS Investors's Health Catalyst position peaked at $221K in Q4 2020.
190 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2021.

Based on QS Investors's 13F filing for Q1 2021, filed 13 May 2021.